Supportive medications and interventions received by prostate cancer survivors: results from the PiCTure study P rostate cancer treatments are associated with various physical after-e ects, including urinary, sexual, and bowel symptoms. 1 ese after-e ects can have an impact on survivors' healthrelated quality of life (HRQoL).
Original Report tions were provided. Men were also asked if they had been told they may become infertile and, if so, whether they had preserved their sperm. e Decisional Regret Scale 8 was used to measure survivors' regret over their entire treatment experience. is 5-item scale, rated on a 5-point Likert scale from 1 (strongly agree) to 5 (strongly disagree) was summed and standardized to a value of 0-100, with higher scores re ecting higher levels of decisional regret. 8 is scale has good psychometric properties 8 and strong reliability in our sample (Cronbach's alpha = 0.85). Responders were categorized as having any regret (score ≥1) or no regret (score = 0). e number of men who reported receiving an intervention was expressed as a percentage of survey responders and of men who reported ever having the relevant aftere ect. Chi-square tests were used to investigate variations in receipt by: age at diagnosis (≤59, 60-69, ≥70 years); time since diagnosis (≤5, 5-10, >10 years); jurisdiction (Republic of Ireland, or Northern Ireland); and primary treatment(s) received (radical prostatectomy [RP] , external beam radiotherapy [EBRT] with androgen deprivation therapy [ADT], EBRT without ADT, brachytherapy, ADT [without other therapies], and active surveillance/watchful waiting). Among survivors who ever experienced an aftere ect, chi-square tests were used to investigate whether the percentage who reported decisional regret di ered depending on whether or not they received the relevant supportive intervention.
Ethics approval was from the Irish College of General Practitioners (Republic of Ireland) and the O ce for Research Ethics Committee Northern Ireland.
Results
In all, 3,348 survivors participated in the survey (adjusted response rate, 54%). Compared with nonresponders, responders were more often from the Republic of Ireland (P = .007), <70 years at diagnosis (P < .001), 5-10 years post diagnosis (P < .001), with low or medium Gleason grade (Gleason scores of ≤6 [good prognosis] and 7, respectively; P < .001), and clinical stage II-IV (P < .001; Table 1 ). Impotence (70%) was the most commonly reported after-e ect, followed by hot ashes/sweats (40%), incontinence (37%), bowel problems (23%), gynaecomastia (19%), and depression (18%; Table 2 ).
Of responders, 2% received an arti cial sphincter, representing 6% of men who ever experienced incontinence post diagnosis (Table 2) . is percentage was signi cantly higher in participants diagnosed longer ago, from the Republic of Ireland, and who received RP (Table 3) . Incontinence medication was received by 8% of participants (21% of those who experienced incontinence). Use varied signicantly by age, jurisdiction, and treatment. For impotence, medications were more commonly used (20% of participants; 28% with impotence) than were injections (5% and 7%, respectively) or penile implants/pumps (2% and 3%, respectively). Use of all 3 types of intervention was highest in men who had RP; injections and implants/pumps were signi cantly more common among younger men. Of those experiencing gynaecomastia, 13% received interventions; receipt was highest in men who had EBRT with ADT, were <5 years post diagnosis and from Northern Ireland. For hot ashes/sweats, 3% of participants (8% who experienced symptoms) received mediations; this was higher in men who had EBRT. Of those who reported depression, 28% received medication; receipt was highest in younger men and in Northern Ireland. Medication for bowel problems was used by 35% of men who experienced these; use was highest in older men, those diagnosed more recently, and those who had EBRT. Sixty percent of men reported having been told they would become infertile; 11 (0.3% of participants) preserved their sperm, 7 from the Republic of Ireland and 4 from Northern Ireland.
A total of 35.6% of survivors reported any decisional regret. Among survivors who ever had an after-e ect, a higher percentage of those who used a supportive intervention reported decisional regret compared with those who did not; this was only statistically signi cant for those using medication or alprostadil injections for impotence ( Table 2) .
Discussion
is study documents, for the rst time, population-based data on patient-reported use of supportive medications and interventions to alleviate adverse e ects of prostate cancer and its treatment. Among survivors who experienced aftere ects, use was highest for bowel problems, impotence, and depression, but even for those, only 28%-35% of men took medication. Although it is possible that some survivors Receipt of medications and other interventions among prostate cancer survivors, by age at diagnosis, time since diagnosis, jurisdiction and primary treatment(s) received;
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12 (1) 66 (7) ** 8 (10) 35 (45) 29 (37) 1 (1) 5 (6) 13 (2) *** Hot ashes/ sweats Medication 27 (4) 50 (4) 28 (4) 45 (4) 37 (4) 23 (4) 65 (4) 40 (4) 15 (14) 27 (26) 41 (39) 2 (2) 37 ( (5) 67 (6) 30 (5) 96 (5) 71 (7)** 57 (35) 28 (17) 57 (35) 1 (1) 17 (10) 5 (3) Bowel problems a Medication 32 (7) 83 (9) 75 (15) *** 93 (13) 61 (9) 36 ( *P < .01; ** P < .005; *** declined medications or other interventions, these low levels of use strongly suggest that not all survivors who might bene t from supports receive them. ere was little evidence that utilisation was higher in survivors diagnosed more recently. is suggests that, although the number of prostate cancer survivors has grown, and there is greater focus on survivorship issues in clinical practice, this has not translated into more men receiving support to manage after-e ects. Care is needed to ensure that the newer models of post-cancer followup being considered or adopted in many settings, 9 do not exacerbate this issue.
As expected, patterns of utilisation varied by treatment(s) received. Higher use of surgical and pharmaceutical interventions to alleviate incontinence among survivors in the Republic of Ireland than in Northern Ireland is likely owing to the higher rate of radical prostatectomy in the Republic of Ireland, whereas greater use of treatments for gynaecomastia in Northern Ireland re ects higher use of hormone therapy there. 10 Other variations in intervention use were more surprising. Younger men were signi cantly more likely to report using supportive interventions for depression and impotence, the latter nding being consistent with ndings in a Swedish population-based study.
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Older men were signi cantly more likely to report interventions for incontinence and bowel problems. Although those trends could be explained by di erences in treatment receipt by age, it is possible that men of di erent ages may be more likely to seek, or be o ered, help for certain types of after-e ects. With the exception of interventions for bowel problems, a higher percentage of men who received intervention(s) for an after-e ect reported decisional regret. ere are a number of possible explanations: these men may have experienced more severe after-e ects, which required interventions; they may have been less satis ed with their posttreatment function and/or more proactive about recovering or treating their after-e ects. is requires further investigation.
is is a large, international, population-based study, the rst such study to describe patient-reported use of supportive care following a range of prostate cancer treatments. Although this study is novel, there are a number of limitations. It is a cross-sectional, descriptive study. We did not ask survivors whether the supportive interventions received matched their needs and wants, and whether they were satis ed with the supportive care received. Furthermore, although the response rate is comparable with other similar studies, 12, 13 it is possible that the supportive care of nonresponders was di erent to that of responders.
Our study included men from 2 jurisdictions with separate health care systems, suggesting that low use of supportive interventions may be common across systems.
ere is a need for further research into patient and health care system factors associated with the receipt of supportive interventions and how satis ed men are with these, in this and other health care settings. Presently, it is clear that more needs to be done in the clinical setting to support prostate cancer survivors manage treatment after-e ects; this in turn could improve survivors' HRQoL.
